The role of aspirin in preventing thrombosis has been accepted by the medical community and patients as a cornerstone of antiplatelet therapy, and as long as there are no contraindications, ischemic cardiovascular disease can be prevented by long-term oral administration of small doses of 75-100 mg aspirin. Small dose aspirin only has such an effect because of the irreversible inhibition of platelet cyclooxygenase by aspirin. Once platelet cyclooxygenase is inhibited, it will lead to the prevention of thrombus formation by cutting off the thrombus formation mechanism to a large extent after the platelets are fully inhibited in their entire life cycle of 7-14 days, whether aggregation or release, etc. It will play an anticoagulant role and widely applied to the primary and secondary prevention of coronary heart disease.